FlightPath Biosciences has filed a notice of an exempt offering of securities to raise $8 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, FlightPath Biosciences is raising $8,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Matthew Tindall played a key…
